Selpercatinib in Early-Stage <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

Maximilian Hochmair

Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna

Yi Yang

Xue-Ning Yang

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

Masahiro Tsuboi

National Cancer Center Hospital East, Kashiwa, Japan

Luis Paz-Ares

Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid

James Chih-Hsin Yang

National Taiwan University Hospital, NTU Cancer Center, Taipei

Lin Wu

The Department of Thoracic Medical Oncology Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China

Hye Ryun Kim

Division of Medical Oncology, Department of Internal Medicine, Yonsei University Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Damian T. Rieke

Charité–Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin

Melissa Johnson

Sarah Cannon Research Institute, Nashville

Benjamin Besse

Nivedita Sharma

Lilly, Indianapolis

Patricia Maeda

Lilly, Indianapolis

Patrick Peterson

Lilly, Indianapolis

Boris Kin Lin

Lilly, Indianapolis

Bente Frimodt-Moller

Lilly, Copenhagen

Jonathan Goldman

University of California, Los Angeles, Los Angeles

Alexander Drilon

Department of Medicine, Memorial Sloan Kettering Cancer Center